Page last updated: 2024-12-07
3-(methoxycarbonyl)amino-beta-carboline
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3-(methoxycarbonyl)amino-beta-carboline: antagonist of sedative effects of benzodiazepines; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 124760 |
| CHEMBL ID | 165882 |
| SCHEMBL ID | 2214365 |
| MeSH ID | M0145421 |
Synonyms (10)
| Synonym |
|---|
| 3-mcabc |
| methyl n-(9h-pyrido[3,4-b]indol-3-yl)carbamate |
| CHEMBL165882 |
| 91985-74-9 |
| 3-(methoxycarbonyl)amino-beta-carboline |
| carbamic acid, 9h-pyrido(3,4-b)indol-3-yl-, methyl ester |
| SCHEMBL2214365 |
| DTXSID70919418 |
| methyl hydrogen 9h-pyrido[3,4-b]indol-3-ylcarbonimidate |
| PD075748 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID40825 | Inhibition of [3H]- flunitrazepam binding to GABA-A Benzodiazepine receptor of rat cerebral cortex membranes | 1985 | Journal of medicinal chemistry, Jun, Volume: 28, Issue:6 | 3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.19
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||